Current antibody diagnostic tests detect too little, too late for a wide range of life-threatening diseases such as HIV, type 1 diabetes and lung cancer. The goal is to enable better patient outcomes in infectious, autoimmune and neoplastic diseases through early antibody detection using ADAP, a breakthrough ultra-sensitive, rapid, highly-specific, massively parallel, antibody detection technology.
Enable Biosciences (ADAP) detection technology enables earlier and more accurate diagnosis empowering more effective treatment and better health outcomes. ADAP is 10,000 times more sensitive than any other antibody diagnostic test, is highly specific, rapid and resists many types of interference that commonly reduce the accuracy of other antibody diagnostics.
We are a team of scientists and a clinician in active practice, acutely aware of the time sensitive challenges with early diagnosis and appropriate intervention to improve patient outcomes on a day-to-day basis. Parents and advocates for improved type I diabetes screening have reached out to us to emphasize the urgency of improved diagnostics for a disease that is devastating to children and families. Their passion and dedication drives our efforts to accelerate and deliver our early diagnostic solution, that can empower immunotherapeutic intervention to improve outcomes for millions of children. Similarly, around the world, the need to detect HIV and treat individuals that are recently infected and are most infectious to others is enormously important if we are to have a meaningful interruption in disease transmission. Lung cancer requires the earliest possible diagnosis for the chance of a better outcome, and we are driven to develop a detection assay that can empower clinicians to intervene at the earliest possible time with appropriate therapeutic options.
Enable Biosciences has been part of JLABS @ QB3 since January 23, 2017. JLABS is an absolutely unique crucible for bioscience innovation and solution acceleration. It is an extraordinary and rich ecosystem of domain experts, forward thinking individuals and invaluable resources. Above all, it is a community of individuals and teams that are incredibly responsive and helpful to innovative companies such as ours. We have connected with, and are pursuing partnership opportunities with, among others, the Janssen Disease Interception Accelerator initiative for type I diabetes as well as programs in immuno-oncology and infectious disease. Together with Johnson & Johnson, we believe we can get our products to the marketplace in a manner that accelerates appropriate therapeutic intervention to ensure better outcomes for patients worldwide.
Meet the Team:
Peter Robinson, PhD
Co-founder and CSO
Peter is an inventor of the core ADAP technology and recently completed his doctorate in chemistry for graduate work performed at UC Berkeley and Stanford. In the course of his degree program, he initiated four projects that apply chemical principles to create tools for the detection glycoproteins and antibodies. These projects have demanded broad expertise in numerous techniques in chemical synthesis, bioconjugation, molecular biology, and immunology. This work forms the basis of several peer-reviewed papers and patents.
Co-founder and CTO
Jason is an inventor of the core ADAP technology and has extensive knowledge of immunology, protein biochemistry and engineering, and physical chemistry. As a graduate student at UC Berkeley and Stanford, he has filed numerous patents in biomedical science and published several peer-reviewed papers in cancer physical biology, diagnostics, and PCR-based assays. In addition, he was a graduate of the UCSF Lean Launchpad program, an NSF-sponsored biotechnology accelerator program. He was a Gold medalist at the 2004 International Chemistry Olympiad.
David Seftel, MD, MBA
Co-founder and CEO
David is a seasoned clinician with a strong background in biotech and entrepreneurship. At Harvard Business School, he co-founded the Health Industry Club which continues today to drive interdisciplinary innovation in the US and around the world. He has worked in a number of startups, including helping to successfully pilot a diagnostic product through 510k certification. He has also advised and mentored numerous startups including those in the UCSF Lean Launchpad program.
Carolyn Bertozzi, PhD
Co-founder and Chair, SAB
Carolyn is a Professor of Chemistry at Stanford and an Investigator with the Howard Hughes Medical Institute. She has been recognized with many honors and awards for her research accomplishments. She is an elected member of the Institute of Medicine, the National Academy of Sciences, and American Academy of Arts and Sciences. She has been awarded the Lemelson-MIT Prize, the Heinrich Wieland Prize, and a MacArthur Foundation Fellowship, among many others. In addition to her academic position, Carolyn recently guided the creation and acquisition of a biotech startup, Redwood Biosciences.